Jonathan Rubin Supernus Pharmaceuticals, Inc. (SUPN) insider trading activity

Jonathan Rubin is SVP, Chief Medical Officer of SUPERNUS PHARMACEUTICALS, INC.. Currently has a direct ownership of 11,015 shares of SUPN, which is worth approximately $495,675. The most recent transaction as insider was on Sep 25, 2025, when has been sold 840 shares (Common Stock) at a price of $46.21 per share, resulting in proceeds of $38,816. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 11K

14.32% 3M change

137.34% 12M change

Total Value Held $495,675

Jonathan Rubin Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 25 2025	SELL Payment of exercise price or tax liability	$38,816 $46.21 p/Share	840 Reduced 7.09%	11,015 Common Stock
Sep 25 2025	BUY Exercise of conversion of derivative security	-	1,875 Added 13.66%	11,855 Common Stock
Mar 05 2025	SELL Payment of exercise price or tax liability	$48,517 $33.05 p/Share	1,468 Reduced 13.22%	9,635 Common Stock
Feb 23 2025	BUY Grant, award, or other acquisition	-	1,250 Added 10.12%	11,103 Common Stock
Feb 22 2025	BUY Grant, award, or other acquisition	-	2,000 Added 16.87%	9,853 Common Stock
Feb 21 2025	SELL Open market or private sale	$36,292 $39.15 p/Share	927 Reduced 10.56%	7,853 Common Stock
Feb 21 2025	BUY Exercise of conversion of derivative security	-	1,875 Added 17.6%	8,780 Common Stock
Dec 27 2024	SELL Payment of exercise price or tax liability	$39,220 $35.59 p/Share	1,102 Reduced 14.32%	6,595 Common Stock
Dec 27 2024	BUY Exercise of conversion of derivative security	-	2,625 Added 26.14%	7,416 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$16,477 $29.06 p/Share	567 Reduced 10.89%	4,641 Common Stock
Feb 23 2024	BUY Grant, award, or other acquisition	-	1,250 Added 19.36%	5,208 Common Stock
Feb 22 2024	SELL Payment of exercise price or tax liability	$8,465 $27.94 p/Share	303 Reduced 7.11%	3,958 Common Stock
Feb 22 2024	BUY Grant, award, or other acquisition	-	750 Added 14.97%	4,261 Common Stock
Dec 22 2023	SELL Payment of exercise price or tax liability	$5,642 $27.66 p/Share	204 Reduced 5.92%	3,243 Common Stock
Dec 22 2023	BUY Exercise of conversion of derivative security	-	600 Added 14.83%	3,447 Common Stock
Feb 22 2023	BUY Grant, award, or other acquisition	-	750 Added 23.1%	2,497 Common Stock
Feb 16 2023	BUY Exercise of conversion of derivative security	-	1,500 Added 50.0%	1,500 Common Stock

Jonathan Rubin

SVP, Chief Medical Officer

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Value

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

Operation

Value

Type

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN

Account